Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 11, 2017
Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program
JERUSALEM, July 11, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced ...
July 11, 2017
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
TEL AVIV, Israel, July 11, 2017 /PRNewswire/ -- Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has ...
July 10, 2017
Ignyta Receives FDA Orphan Drug Designation for Entrectinib for Treatment of NTRK Fusion-Positive Solid Tumors
SAN DIEGO--(BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) ...
July 10, 2017
Reata Pharmaceuticals, Inc. Receives Orphan Drug Designation for Bardoxolone Methyl for the Treatment of Alport Syndrome
IRVING, Texas, July 10, 2017 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or “the Company”), a clinical-stage biopharmaceutical company, today announced that the United ...
July 10, 2017
AC Immune Provides Seven Updates on its Pipeline and Technology at the Alzheimer's Association International Conference
Lausanne, Switzerland, July 10, 2017 - AC Immune SA (ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates ...
July 10, 2017
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
ROCKVILLE, Md., July 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
July 7, 2017
Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S.
Copenhagen, July 6, 2017 - Zealand Pharma ("Zealand" or the "Company") announces that it has today filed a Form F-1 Registration Statement for a proposed initial ...
July 6, 2017
Advaxis Announces Change in Leadership
PRINCETON, N.J.--(BUSINESS WIRE) -- Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc.(ADXS), a late-stage biotechnology company focused on the discovery, development ...
July 6, 2017
Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York
SAN DIEGO, July 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, announced today that they will host a ...
July 6, 2017
Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program
SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
July 6, 2017
Prometic announces closing of equity offerings for aggregate gross proceeds of $61.7 million
LAVAL, QC , July 6, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) ("Prometic" or the "Corporation") announced today that it has closed the previously ...
July 5, 2017
Onxeo Announces Positive Preclinical Proof of Concept Results Confirming AsiDNA™ Activity via Systemic Administration
Onxeo S.A. (ONXEO.PA) (NASDAQ OMX:ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs for the treatment of orphan ...
July 5, 2017
BioLife Solutions Modifies Existing Credit Facility
BOTHELL, Wash., July 5, 2017 /PRNewswire/ -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage ...
July 5, 2017
CytoSorbents Receives Additional $5 Million in Non-Dilutive Debt Financing from Bridge Bank
MONMOUTH JUNCTION, N.J., July 5, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that on June 30, 2017 it received an additional ...
July 5, 2017
Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
July 5, 2017
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif.--(BUSINESS WIRE) -- Aimmune Therapeutics, Inc. (AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of ...
July 5, 2017
IMMUNE Pharmaceuticals' Oncology Subsidiary, CYTOVIA, Announces Additional Clinical Trial Results on the Efficacy of Ceplene® in Combination with Low-Dose IL-2 in Patients With Acute Myeloid Leukemia, Recently Published in Leukemia, a Leading Hematology Journal
NEW YORK, July 5, 2017 /PRNewswire/ -- Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company (IMNP) ("Immune" or the "Company") announced ...
July 5, 2017
Oramed Announces Dual-Listing on Tel Aviv Stock Exchange
JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced ...
July 5, 2017
Minerva Neurosciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
WALTHAM, Mass., July 05, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced public ...
July 5, 2017
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease
DUBLIN, Ireland, July 05, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of ...
Page 152 of 162